DE69330690T2 - Verfahren zur Herstellung hoch-wasserlöslicher Zyklodextrinkomplexe - Google Patents

Verfahren zur Herstellung hoch-wasserlöslicher Zyklodextrinkomplexe

Info

Publication number
DE69330690T2
DE69330690T2 DE69330690T DE69330690T DE69330690T2 DE 69330690 T2 DE69330690 T2 DE 69330690T2 DE 69330690 T DE69330690 T DE 69330690T DE 69330690 T DE69330690 T DE 69330690T DE 69330690 T2 DE69330690 T2 DE 69330690T2
Authority
DE
Germany
Prior art keywords
optionally substituted
derivative
highly water
soluble cyclodextrin
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69330690T
Other languages
English (en)
Other versions
DE69330690D1 (de
Inventor
Yoshihiro Ohmachi
Yoshihiro Tsugawa
Akihiro Nagai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of DE69330690D1 publication Critical patent/DE69330690D1/de
Publication of DE69330690T2 publication Critical patent/DE69330690T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
DE69330690T 1992-01-30 1993-01-28 Verfahren zur Herstellung hoch-wasserlöslicher Zyklodextrinkomplexe Expired - Fee Related DE69330690T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1523692 1992-01-30
JP33202192 1992-12-11

Publications (2)

Publication Number Publication Date
DE69330690D1 DE69330690D1 (de) 2001-10-11
DE69330690T2 true DE69330690T2 (de) 2002-06-20

Family

ID=26351355

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69330690T Expired - Fee Related DE69330690T2 (de) 1992-01-30 1993-01-28 Verfahren zur Herstellung hoch-wasserlöslicher Zyklodextrinkomplexe

Country Status (5)

Country Link
US (1) US5536623A (de)
EP (1) EP0555693B1 (de)
AT (1) ATE205092T1 (de)
CA (1) CA2088428A1 (de)
DE (1) DE69330690T2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
KR100357542B1 (ko) * 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
KR100357541B1 (ko) * 1998-05-15 2002-10-18 주식회사종근당 5-데메톡시 푸마질롤 유도체 및 그 제조방법
CA2418224C (en) * 2000-08-10 2010-02-09 Takeda Chemical Industries, Ltd. Pharmaceutical composition
JP4922507B2 (ja) * 2000-08-10 2012-04-25 武田薬品工業株式会社 医薬組成物
KR100451485B1 (ko) * 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
CN102123586A (zh) * 2008-07-18 2011-07-13 法弗根股份有限公司 治疗超重或肥胖受试者的方法
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
EP2486004B1 (de) 2009-10-09 2017-05-03 Zafgen, Inc. Sulfonverbindungen zur verwendung in der behandlung von adipositas
BR112012016793A2 (pt) 2010-01-08 2018-07-31 Zafgen Corp compostos tipo fumagilol e métodos de fazer e usar os mesmos
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
WO2012012642A1 (en) 2010-07-22 2012-01-26 Zafgen Corporation Tricyclic compounds and methds of making and using same
CA2817199C (en) 2010-11-09 2019-01-15 Zafgen, Inc. Crystalline solids of a metap-2 inhibitor and methods of making and using same
MX2013005989A (es) 2010-11-29 2013-08-21 Zafgen Inc Tratamiento de obesidad utilizando administracion no diaria de 6-o-(4-dimetilaminoetoxi)cinamoil fumagilol.
US9321740B2 (en) 2011-01-26 2016-04-26 Zafgen, Inc. Tetrazole compounds and methods of making and using same
BR112013023056A2 (pt) 2011-03-08 2018-10-09 Zafgen Inc derivados de oxaespiro [2,5] octano e análogos
EP2705030B1 (de) 2011-05-06 2016-07-27 Zafgen, Inc. Teilweise gesättigten trizyklishen verbindungen, deren herstellung und verwendung
EP2705035B1 (de) 2011-05-06 2016-12-14 Zafgen, Inc. Tricyclische pyrazolsulfonamidverbindungen sowie verfahren und herstellung zu ihrer herstellung
AU2012253759B2 (en) 2011-05-06 2016-01-21 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
EP2763671A2 (de) 2011-10-03 2014-08-13 Zafgen, Inc. Verfahren zur behandlung von altersbedingten erkrankungen
WO2013109735A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
AU2013209723B2 (en) 2012-01-18 2016-11-24 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
KR20150016303A (ko) 2012-05-07 2015-02-11 자프겐 인크. 6-o-(4-디메틸아미노에톡시) 신나모일 푸마지롤의 옥살레이트 염의 다형체 염 및 이의 제조 및 사용 방법
CA2872876A1 (en) 2012-05-08 2013-11-14 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
CN104364251B (zh) 2012-05-09 2017-02-22 扎夫根股份有限公司 烟曲霉醇型化合物及其制备和使用方法
CN104870433A (zh) 2012-11-05 2015-08-26 扎夫根股份有限公司 三环化合物及其制备方法和用途
MX2015005734A (es) 2012-11-05 2016-02-10 Zafgen Inc Metodos de tratamiento de enfermedades hepaticas.
CN104918928A (zh) 2012-11-05 2015-09-16 扎夫根股份有限公司 三环化合物及其制备方法和用途
MX362391B (es) 2013-03-14 2019-01-15 Zafgen Inc Métodos de tratamiento de enfermedad renal y otros trastornos.
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN113321753B (zh) * 2021-05-19 2022-08-30 山东滨州智源生物科技有限公司 多元糖基氨基酸基环糊精衍生物、水凝胶的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0764884B2 (ja) * 1986-11-27 1995-07-12 株式会社トクヤマ シクロデキストリン組成物
CA1333363C (en) * 1988-01-19 1994-12-06 Judah Folkman Angiogenesis inhibitor comprising fumagillin
ES2058503T5 (es) * 1988-03-29 1999-04-16 Univ Florida Formulaciones farmaceuticas para uso parenteral.
US5227372A (en) * 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
TW282399B (de) * 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
EP0519428B1 (de) * 1991-06-21 2000-09-20 Takeda Chemical Industries, Ltd. Zyklodextrin-Zusammensetzung enthaltend Fumagillol-Derivate

Also Published As

Publication number Publication date
ATE205092T1 (de) 2001-09-15
EP0555693B1 (de) 2001-09-05
CA2088428A1 (en) 1993-07-31
EP0555693A1 (de) 1993-08-18
US5536623A (en) 1996-07-16
DE69330690D1 (de) 2001-10-11

Similar Documents

Publication Publication Date Title
DE69330690T2 (de) Verfahren zur Herstellung hoch-wasserlöslicher Zyklodextrinkomplexe
TW282399B (de)
DE3867268D1 (de) Heterocyclische verbindungen und deren herstellung und verwendung.
DE68923274D1 (de) Verfahren zur herstellung eines mit metall-radionuklid-markierten proteins.
JP3673888B2 (ja) ポルフィリン類金属錯体の製造方法
ATE145209T1 (de) Tri-aza-makrocyclen und verfahren zu ihrer herstellung
ATE138571T1 (de) Verwendung von dioxabicyclo (3.3.0>octane derivaten zur herstellung eines arzneimittels zur hemmung des cholesterinmetabolismus.
HUP0102599A2 (hu) Artemizinin-származékok, eljárás a vegyületek előállítására, és a vegyületeket tartalmazó gyógyszerészeti készítmények
Lydon et al. Synthesis and characterization of coordinated disulfides. Single-crystal structural analysis of [(en) 2Co (S (SC (CH3) 2COOH) C (CH3) 2COO)](ClO4) 2. cntdot. H2O
Derek Kinetics of aminolysis of some benzoyl fluorides and benzoic anhydrides in non-hydroxylic solvents
HUP0302912A2 (hu) Béta-tio-aminosavak, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ATE96464T1 (de) Verfahren zur herstellung von thiolen.
DE69013528D1 (de) Eine Perfluoralkylgruppe enthaltende Verbindung.
ATE122343T1 (de) Triazolyl-hydrazidderivate und verfahren zu ihrer herstellung.
RO92245A (ro) Procedeu pentru prepararea unor derivati de 1,6-naftiridina
ATE215934T1 (de) Neue histidinderivate, verfahren zu ihrer herstellung und ihre verwendung als mittel gegen freie radikale
KR890000406A (ko) 신나모일아미드 유도체, 그들의 제조방법, 그들을 함유하는 제약학적 조성물 및 그들의 사용
ATE7917T1 (de) Pyranoindolderivat und verfahren zu seiner herstellung.
HU895522D0 (en) Process for the preparation of new thienyl-oxy-alkyl-amine derivatives and pharmaceutical compositions containing them
Elliott et al. Pentaammineruthenium (II/III) imidazole and imidazolate complexes of 2-carboxylatoimidazolate and 2-imidazolecarboxaldehyde
KR910006238A (ko) 피라즐-3-카르복스아미드
SE9802643D0 (sv) 2,3-Disubstituerade cyklopentanonderivat, förfarande för framställning av den och medicinsk användning därav
DE60232786D1 (de) "komplexkatalysator, verfahren zur herstellung des komplexkatalysators und verfahren zur herstellung von alkoholderivaten mit dem komplexkatalysator"
IL106692A (en) AZIDOALKYL DERIVATIVES AND THEIR USE FOR THE PREPARATION OF 99mTc COMPLEXES FOR IMAGING
Le Bozec et al. Carbon disulphide iron complexes as a source of bis (trifluoroacetato) iron derivatives

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee